Crisis management, stable supply and medical support in response to COVID-19
First written in FY2020. 2 of 5 entries say "Advanced", first in FY2021. Latest entry: FY2022.
0 other companies' latest entry also says "Advanced".
- FY2022AdvancedAnnual report
「In December 2021, together with Professor Takeda Akihiro (竹田 晋浩), President of the NPO Japan ECMOnet, the Company received the Prime Minister’s Prize of the 5th Japan Medical Research and Development Awards for its achievements in continuously improving the durability of ECMO, a medical device that supports cardiopulmonary function, through research and development to enable long-term use, supporting personnel in clinical settings, and improving the survival rate of critically ill patients with COVID-19.」
Disclosed the award of the Prime Minister’s Prize for contributions to infection prevention and treatment through ECMO improvements and personnel support for clinical settings. - FY2021AdvancedAnnual report
「During the COVID-19 pandemic, the Company strengthened management oversight across the Group with a focus on crisis management. It sought to maintain a flexible operating structure capable of responding quickly to rapidly changing conditions, including by adding safeguards for financial soundness and liquidity, reviewing the earnings outlook at shorter intervals, and implementing stricter income and expense controls than in normal times.」
The COVID-19 response was developed into company-wide crisis management covering liquidity, the earnings outlook, and income and expense controls, in addition to the basic policies of employee health, stable supply, and healthcare support. - FY2021-Q3Continued impact mitigationAnnual report
「Although the impact of lower demand became apparent in the Cardiovascular Company, the impact on the Hospital Company and Blood and Cell Technologies Company was relatively limited, and demand for some products increased. As a result, the Company was able to alleviate the impact of the spread of COVID-19 to a certain extent on a company-wide basis.」
The Company explained that, while the impact of lower demand continued in the Cardiovascular Company, the impact on the Hospital and Blood and Cell Technologies businesses was relatively limited, and increased demand for some products enabled it to alleviate the overall impact to a certain extent. - FY2021-Q1Business impact alleviated to a certain extentAnnual report
「Although the impact on the Cardiovascular Company became apparent, the impact on the Hospital Company and Blood and Cell Technologies Company was relatively limited, and demand for some products increased. As a result, the Company was able to alleviate the impact of the spread of the novel coronavirus to a certain extent on a company-wide basis.」
The Company explained that, while the impact on the Cardiovascular Company became apparent, the impact on the Hospital and Blood and Cell Technologies businesses was relatively limited, and increased demand for some products enabled it to alleviate the overall impact to a certain extent. - FY2020First statedAnnual report
「In response to the impact of the spread of the novel coronavirus, the Company is conducting its business activities based on the following 3 basic policies, founded on its corporate philosophy, core values, and Group Basic Business Continuity Regulations: giving top priority to the health and safety of all employees; making every effort to ensure a stable supply of products so that healthcare can continue; and mobilizing the capabilities of the Terumo Group to actively contribute to preventing and treating infection with the virus.」
As its response to the spread of the infection, the Company set out, for the first time in a systematic manner, 3 basic policies: employee health and safety, a stable supply of medical devices, and contributions to infection prevention and treatment. It also began strengthening management oversight with a focus on crisis management from 1 April 2020.